Curie.Bio Raises $380M for VC Fund, Aims to Support Biotech Founders

Curie.Bio, a venture capital firm based in Cambridge, Massachusetts, has successfully secured $380 million for its latest fund. This brings the total funds raised by the company to almost $1 billion.

The newly raised capital will be primarily allocated to Series A rounds for clinical proof-of-concept studies in successful early-stage therapeutics companies. Curie.Bio aims to provide founders with access to top drug hunters, operators, and R&D services, supporting them from the idea stage through to generating meaningful clinical data. The firm's unique model focuses on minimizing long-term dilution for founders while offering immediate access to essential industry resources.

Curie.Bio has also facilitated the development of clinic-ready therapies with blockbuster potential in a short timeframe, enabling founders to raise substantial equity in their companies. Read the full press release here.